- Home
- MLGO vs LPTX Comparison
MLGO vs LPTX Comparison
Compare MLGO & LPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLGO
- LPTX
- Stock Information
- Founded
- MLGO 2018
- LPTX 2011
- Country
- MLGO China
- LPTX United States
- Employees
- MLGO N/A
- LPTX N/A
- Industry
- MLGO EDP Services
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MLGO Technology
- LPTX Health Care
- Exchange
- MLGO Nasdaq
- LPTX Nasdaq
- Market Cap
- MLGO 15.6M
- LPTX 14.7M
- IPO Year
- MLGO N/A
- LPTX N/A
- Fundamental
- Price
- MLGO $14.66
- LPTX $0.35
- Analyst Decision
- MLGO
- LPTX Hold
- Analyst Count
- MLGO 0
- LPTX 1
- Target Price
- MLGO N/A
- LPTX N/A
- AVG Volume (30 Days)
- MLGO 33.0M
- LPTX 3.3M
- Earning Date
- MLGO 04-28-2025
- LPTX 08-11-2025
- Dividend Yield
- MLGO N/A
- LPTX N/A
- EPS Growth
- MLGO N/A
- LPTX N/A
- EPS
- MLGO 16.40
- LPTX N/A
- Revenue
- MLGO $74,185,505.00
- LPTX N/A
- Revenue This Year
- MLGO N/A
- LPTX N/A
- Revenue Next Year
- MLGO N/A
- LPTX N/A
- P/E Ratio
- MLGO $1.08
- LPTX N/A
- Revenue Growth
- MLGO N/A
- LPTX N/A
- 52 Week Low
- MLGO $0.50
- LPTX $0.22
- 52 Week High
- MLGO $59.40
- LPTX $4.79
- Technical
- Relative Strength Index (RSI)
- MLGO 32.95
- LPTX 52.39
- Support Level
- MLGO $18.00
- LPTX $0.32
- Resistance Level
- MLGO $26.40
- LPTX $0.36
- Average True Range (ATR)
- MLGO 3.16
- LPTX 0.03
- MACD
- MLGO 2.76
- LPTX 0.01
- Stochastic Oscillator
- MLGO 7.56
- LPTX 86.94
About MLGO MicroAlgo Inc.
MicroAlgo Inc is divided into two segments: Central processing algorithm services & Intelligent chips and services. The majority is from the Central Processing Algorithm Services. which refers to a range of computing algorithms, analytical algorithms, recommendation algorithms, & acceleration algorithms. The businesses engaged in internet advertisement, game development, intelligent chip design, finance, retail, & logistics depend on the ability to process & analyze data with optimized computing software & hardware capable of handling the data workload. Intelligent chips and services revenues include revenues generated from the resale of intelligent chips. All of the Company's net revenues were generated in the PRC, Hong Kong, & Singapore, out of which the majority is from the PRC.
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.